NMTC — Stock Film
STOCK FILMSCENE 1/10NMTC · $1.56
Stock Expert AI presents
NMTC
NeuroOne Medical Technologies Corporation
~5 min film100% real numbersplain English
WHAT DOES THIS COMPANY DO?
NeuroOne Medical Technologies Corporation. What it actually does.

Develops thin film electrode technology for medical applications. Focuses on solutions for continuous electroencephalogram (cEEG) recording. Now — the numbers.

on the stock market since 2018
18 employees
$13.6M market value
Revenue last year:
$12.1M
The loss that same year:
$3.6M
For every $1 it earns, the company spends $1.3.

The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 187% a year over the last 4 years. Red columns mark years that ended in a loss.

$178K
2021
2022
2023
2024
$12.1M
2025
In the vault right now:
$6.6M
DEBT: $267K
At this pace, that money lasts about 1.8 years.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
19
very weak

Clearly below the class average.

FINANCIAL STRENGTH
57
average

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
33
very weak

Clearly below the class average.

GROWTH
76
strong

Clearly above the class average — a step short of the very top.

PRICE MOMENTUM
13
very weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

Business Quality: Profit power and business quality trail similar companies in the sector.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 94% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Sales keep climbing

Over the last 4 years, sales grew about 187% a year on average.

2
THE BRIGHT SIDE · 2/2
The product is selling

Sales run at $12.1M a year. A small number, but proof the product has real buyers.

1
THE RISKS · 1/2
Small sales, big loss

A loss of $3.6M against $12.1M in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts about 1.8 years. After that, the company needs to find new money.

FINALE · THE GRADE
F
21 / 100 · MoonshotScore

On our five-subject report card, NMTC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: NMTC is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

Analysts’ average target sits above today’s price, yet the valuation grade (33/100) says the stock isn’t cheap.

What would you like to do next?
Open the stock page →

Not covered, because the filings we hold do not carry it: the revenue breakdown.

This was a film — not investment advice.
Data: FMP & company filings
Sep 11, 2026 · stockexpertai.com · Stock Film